Paliperidone
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Paliperidone |
| DrugBank ID | DB01267 |
| Brand Names (EU) | Invega |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.96% |
Approved Indication (EMA)
Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. Invega is indicated for the treatment of schizoaffective disorder in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | schizophrenia | 99.96% | DL |
| 2 | retinal dystrophy with or without extraocular anomalies | 99.92% | DL |
| 3 | schizophreniform disorder | 99.91% | DL |
| 4 | myopia X-linked | 99.91% | DL |
| 5 | syndromic myopia | 99.91% | DL |
| 6 | hydranencephaly (disease) | 99.91% | DL |
| 7 | congenital disorder of glycosylation with defective fucosylation | 99.90% | DL |
| 8 | myopia 26, X-linked, female-limited | 99.89% | DL |
| 9 | psychotic disorder | 99.88% | DL |
| 10 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.87% | DL |
| 11 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99.86% | DL |
| 12 | atypical glycine encephalopathy | 99.83% | DL |
| 13 | treatment-refractory schizophrenia | 99.80% | DL |
| 14 | early-onset schizophrenia | 99.79% | DL |
| 15 | mental disorder | 99.59% | DL |
| 16 | REM sleep behavior disorder | 99.49% | DL |
| 17 | psychosexual disorder | 99.38% | DL |
| 18 | schizoaffective disorder | 99.04% | DL |
| 19 | manic bipolar affective disorder | 98.92% | DL |
| 20 | postpartum psychosis | 98.86% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.